FDA Urges HCPs to Follow Authorized Dosing Schedules for COVID-19 Vaccines
Additional research from the vaccine manufacturers would be needed to support any changes to the dosing schedule.
Additional research from the vaccine manufacturers would be needed to support any changes to the dosing schedule.
Moderna is increasing its baseline production estimates for its COVID-19 vaccine from 500 to 600 million doses for 2021.
The vaccine candidate contains the Company’s saponin-based Matrix-M™ adjuvant technology to enhance and prolong immune responses.
Study authors evaluated the effects of methotrexate discontinuation on influenza vaccine response during the COVID-19 pandemic.
The FDA has granted an EUA to Moderna’s COVID-19 vaccine, mRNA-1237, for active immunization.
A total of 131 cases of COVID-19 were reported in the interim analysis, with no hospitalizations or severe cases noted in participants who received the vaccine.
A new vaccine developed by Pfizer and the German biotechnology firm BioNTech was more than 90% effective at protecting people from COVID-19.
A phase 3 trial evaluating the vaccine candidate mRNA-1273 against COVID-19 met its primary efficacy end point in the first interim analysis.
In the event of a likely scarcity of COVID-19 vaccines, a framework must be developed to inform who should get priority.
An inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine seems safe and induces humoral responses.